A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine–cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer

International Urology and Nephrology · Published 2026-07-25 · DOI 10.1007/s11255-026-05275-1

Authors (8)

Biao Zhang, Cheng Wang, Shujun Yang, Xuan Li, Can Li, Hong Chang, Su Zhang, Panfeng Shang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Zhang, B., Wang, C., Yang, S., et al. (2026). A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine–cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05275-1

Related articles